Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03764930
Other study ID # yanghs201812
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2013
Est. completion date November 30, 2018

Study information

Verified date December 2018
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.


Description:

Retrospective study of the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma and to alert ophthalmologists to the possibility of RB in children presenting with or without trauma-related symptoms and signs.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date November 30, 2018
Est. primary completion date August 1, 2018
Accepts healthy volunteers
Gender All
Age group 1 Month to 80 Years
Eligibility Inclusion Criteria:

- The consecutive patients with RB managed at the ocular oncology service of Zhongshan Ophthalmic Center, Sun Yat-sen University, between January 2013 and August 2018.

Exclusion Criteria:

- The patients who didn't have undergone trauma before diagnosis of RB.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Unsuspected Retinoblastoma
To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.

Locations

Country Name City State
China Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Status Outcome at last follow-up between January 2013 and August 2018
Secondary Trauma incidence of RB patients We reviewed the computerized diagnostic records of consecutive patients with RB managed at the ocular oncology service of Zhongshan Ophthalmic Center, Sun Yat-sen University, between January 2013 and August 2018. The charts of those patients who had undergone trauma before diagnosis of RB were selected. In addition, we identified the preschool-aged children (age 0-6 years) who underwent surgical treatment for ocular trauma at our hospital during the corresponding period. Then, we calculated the incidence of trauma among RB patients. between January 2013 and August 2018
Secondary RB incidence of pre-school patients with trauma history We reviewed the computerized diagnostic records of consecutive patients with RB managed at the ocular oncology service of Zhongshan Ophthalmic Center, Sun Yat-sen University, between January 2013 and August 2018. The charts of those patients who had undergone trauma before diagnosis of RB were selected. In addition, we identified the preschool-aged children (age 0-6 years) who underwent surgical treatment for ocular trauma at our hospital during the corresponding period. Then, we calculated the incidence of RB among pre-school patients with trauma history. between January 2013 and August 2018
See also
  Status Clinical Trial Phase
Recruiting NCT04564521 - Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. N/A
Recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Withdrawn NCT01151748 - Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Active, not recruiting NCT00360750 - Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye N/A
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Enrolling by invitation NCT06227962 - Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Terminated NCT02617862 - PCI Imaging System in Pediatric Ophthalmology N/A
Recruiting NCT02329002 - SPT Screening in Irradiated Hereditary Retinoblastoma Survivors N/A
Terminated NCT01466855 - A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Early Phase 1
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Completed NCT00002515 - Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Completed NCT06367569 - Evaluation of MRI of the Pineal Gland in Retinoblastoma
Completed NCT02193724 - Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
Completed NCT01884194 - Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging N/A
Terminated NCT01393769 - Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Phase 2
Completed NCT00006246 - Busulfan in Treating Children and Adolescents With Refractory CNS Cancer Phase 1
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1